Antidepressant medication use, weight gain, and risk of type 2 diabetes: a population-based study.
OBJECTIVE: To examine antidepressant medication use as a risk factor for type 2 diabetes and weight gain. RESEARCH DESIGN AND METHODS: A series of nested studies within a prospective cohort of 151,347 working-aged men and women including 9,197 participants with continuing antidepressant medication,...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2010
|
| _version_ | 1826294996341358592 |
|---|---|
| author | Kivimäki, M Hamer, M Batty, G Geddes, J Tabak, A Pentti, J Virtanen, M Vahtera, J |
| author_facet | Kivimäki, M Hamer, M Batty, G Geddes, J Tabak, A Pentti, J Virtanen, M Vahtera, J |
| author_sort | Kivimäki, M |
| collection | OXFORD |
| description | OBJECTIVE: To examine antidepressant medication use as a risk factor for type 2 diabetes and weight gain. RESEARCH DESIGN AND METHODS: A series of nested studies within a prospective cohort of 151,347 working-aged men and women including 9,197 participants with continuing antidepressant medication, 224 with severe depression, and 851 with incident type 2 diabetes during a mean follow-up of 4.8 years, as indicated by national health and prescription registers (the Public Sector study, Finland 1995-2005). RESULTS: In the first analysis, the case subjects were individuals with incident type 2 diabetes compared with matched diabetes-free control subjects. Antidepressant use of ≥ 200 defined daily doses was associated with a doubling of diabetes risk in both participants with no indication of severe depression (odds ratio 1.93 [95% CI 1.48-2.51]) and participants with severe depression (2.65 [1.31-5.39]). In further analyses, the exposed group was antidepressant users and the reference group was nonusers matched for depression-related characteristics. The 5-year absolute risk of diabetes was 1.1% for nonusers, 1.7% for individuals treated with 200-399 defined daily doses a year, and 2.3% for those with ≥ 400 defined daily doses (P(trend) < 0.0001). An average self-reported weight gain, based on repeated surveys, was 1.4 kg (2.5%) among nonusers and 2.5 kg (4.3%) among users of ≥ 200 defined daily doses (P(trend) < 0.0001). Separate analyses for tricyclic antidepressants and selective serotonin reuptake inhibitors replicated these findings. CONCLUSIONS: In these data, continuing use of antidepressant medication was associated with an increased relative risk of type 2 diabetes, although the elevation in absolute risk was modest. |
| first_indexed | 2024-03-07T03:54:18Z |
| format | Journal article |
| id | oxford-uuid:c25480aa-d6a7-45e0-8573-e3c2ccbb4e9a |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T03:54:18Z |
| publishDate | 2010 |
| record_format | dspace |
| spelling | oxford-uuid:c25480aa-d6a7-45e0-8573-e3c2ccbb4e9a2022-03-27T06:08:13ZAntidepressant medication use, weight gain, and risk of type 2 diabetes: a population-based study.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:c25480aa-d6a7-45e0-8573-e3c2ccbb4e9aEnglishSymplectic Elements at Oxford2010Kivimäki, MHamer, MBatty, GGeddes, JTabak, APentti, JVirtanen, MVahtera, JOBJECTIVE: To examine antidepressant medication use as a risk factor for type 2 diabetes and weight gain. RESEARCH DESIGN AND METHODS: A series of nested studies within a prospective cohort of 151,347 working-aged men and women including 9,197 participants with continuing antidepressant medication, 224 with severe depression, and 851 with incident type 2 diabetes during a mean follow-up of 4.8 years, as indicated by national health and prescription registers (the Public Sector study, Finland 1995-2005). RESULTS: In the first analysis, the case subjects were individuals with incident type 2 diabetes compared with matched diabetes-free control subjects. Antidepressant use of ≥ 200 defined daily doses was associated with a doubling of diabetes risk in both participants with no indication of severe depression (odds ratio 1.93 [95% CI 1.48-2.51]) and participants with severe depression (2.65 [1.31-5.39]). In further analyses, the exposed group was antidepressant users and the reference group was nonusers matched for depression-related characteristics. The 5-year absolute risk of diabetes was 1.1% for nonusers, 1.7% for individuals treated with 200-399 defined daily doses a year, and 2.3% for those with ≥ 400 defined daily doses (P(trend) < 0.0001). An average self-reported weight gain, based on repeated surveys, was 1.4 kg (2.5%) among nonusers and 2.5 kg (4.3%) among users of ≥ 200 defined daily doses (P(trend) < 0.0001). Separate analyses for tricyclic antidepressants and selective serotonin reuptake inhibitors replicated these findings. CONCLUSIONS: In these data, continuing use of antidepressant medication was associated with an increased relative risk of type 2 diabetes, although the elevation in absolute risk was modest. |
| spellingShingle | Kivimäki, M Hamer, M Batty, G Geddes, J Tabak, A Pentti, J Virtanen, M Vahtera, J Antidepressant medication use, weight gain, and risk of type 2 diabetes: a population-based study. |
| title | Antidepressant medication use, weight gain, and risk of type 2 diabetes: a population-based study. |
| title_full | Antidepressant medication use, weight gain, and risk of type 2 diabetes: a population-based study. |
| title_fullStr | Antidepressant medication use, weight gain, and risk of type 2 diabetes: a population-based study. |
| title_full_unstemmed | Antidepressant medication use, weight gain, and risk of type 2 diabetes: a population-based study. |
| title_short | Antidepressant medication use, weight gain, and risk of type 2 diabetes: a population-based study. |
| title_sort | antidepressant medication use weight gain and risk of type 2 diabetes a population based study |
| work_keys_str_mv | AT kivimakim antidepressantmedicationuseweightgainandriskoftype2diabetesapopulationbasedstudy AT hamerm antidepressantmedicationuseweightgainandriskoftype2diabetesapopulationbasedstudy AT battyg antidepressantmedicationuseweightgainandriskoftype2diabetesapopulationbasedstudy AT geddesj antidepressantmedicationuseweightgainandriskoftype2diabetesapopulationbasedstudy AT tabaka antidepressantmedicationuseweightgainandriskoftype2diabetesapopulationbasedstudy AT penttij antidepressantmedicationuseweightgainandriskoftype2diabetesapopulationbasedstudy AT virtanenm antidepressantmedicationuseweightgainandriskoftype2diabetesapopulationbasedstudy AT vahteraj antidepressantmedicationuseweightgainandriskoftype2diabetesapopulationbasedstudy |